Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLAME-1: High-Dose Firmonertinib + Bevacizumab + Intrathecal Pemetrexed in EGFR-Mutated NSCLC With Leptomeningeal Metastasis
NCT06971406Phase 2Not yet recruiting
- Start
- May 2025
- Primary completion
- Jan 2027
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of furmonertinib in non-small cell lung cancer (NSCLC) and leptomeningeal metastasis (LM). Primary endpoint: Overall Survival (EGFR Ex19del/L858R) up to 36 months. Planned start May 2025; status: not yet recruiting.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)leptomeningeal metastasis (LM)
Beyond the preview
Go deeper on NCT06971406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06971406.